Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
affitope ad02
- Development stage
- Discontinued
- Lead developer
- AC Immune
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptides, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Affitope AD02 is a synthetic peptide-based vaccine developed for the treatment of Alzheimer's disease. It consists of a six-amino-acid peptide that mimics the N-terminus of amyloid-beta (Aβ), designed to elicit an immune response specifically against Aβ without cross-reacting with amyloid precursor protein (APP). The goal is to generate anti-Aβ antibodies while minimizing T cell-mediated inflammatory responses, potentially offering a favorable safety profile. Developed using AFFITOME technology by AFFiRiS, this subunit vaccine was evaluated in phase 1 and phase 2 clinical trials for early-stage Alzheimer's disease but did not meet primary or secondary endpoints in phase 2 studies and its development has been discontinued[1][2][3][5][6].
- Other names
- Alzheimer's disease vaccine 2 (AFFITOPE)
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on affitope ad02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on affitope ad02.